These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 26661592)

  • 1. Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIB-IV gastric cancer.
    Yoon S; Yoo C; Ryu MH; Kang MJ; Ryoo BY; Park SR; Yook JH; Oh ST; Yoo MW; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):182-189. PubMed ID: 26661592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis.
    Kim JH; Park SR; Ryu MH; Ryoo BY; Kim KP; Kim BS; Yoo MW; Yook JH; Kim BS; Kim J; Byeon SJ; Kang YK
    Cancer Res Treat; 2018 Apr; 50(2):518-529. PubMed ID: 28546521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study.
    Maeda O; Matsuoka A; Miyahara R; Funasaka K; Hirooka Y; Fukaya M; Nagino M; Kodera Y; Goto H; Ando Y
    World J Gastroenterol; 2017 Feb; 23(6):1090-1097. PubMed ID: 28246483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial.
    Noh SH; Park SR; Yang HK; Chung HC; Chung IJ; Kim SW; Kim HH; Choi JH; Kim HK; Yu W; Lee JI; Shin DB; Ji J; Chen JS; Lim Y; Ha S; Bang YJ;
    Lancet Oncol; 2014 Nov; 15(12):1389-96. PubMed ID: 25439693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.
    Cheng X; Wu D; Xu N; Chen L; Yan Z; Chen P; Zhou L; Yu J; Cui J; Li W; Wang C; Feng W; Wei Y; Yu P; Du Y; Ying J; Xu Z; Yang L; Zhang Y
    BMC Cancer; 2021 Jan; 21(1):56. PubMed ID: 33435909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02.
    Choi YH; Oh SC; Kim JS; Nam SH; Kim BS; Cho SH; Chung IJ; Song EK; Yim CY; Baek JH; Jeung HC; Hong YS; Yang SH; Kang HJ
    Cancer Chemother Pharmacol; 2012 Nov; 70(5):665-72. PubMed ID: 22926638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer.
    Lee SS; Jeung HC; Chung HC; Noh SH; Hyung WJ; Ahn JY; Rha SY
    Invest New Drugs; 2012 Feb; 30(1):357-63. PubMed ID: 20734110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase II study of adjuvant S-1/cisplatin chemotherapy followed by S-1-based chemoradiotherapy for D2-resected gastric cancer.
    Shim HJ; Kim KR; Hwang JE; Bae WK; Ryu SY; Park YK; Nam TK; Chung IJ; Cho SH
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):605-12. PubMed ID: 26846507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival Outcomes of Two Phase 2 Studies of Adjuvant Chemotherapy with S-1 Plus Oxaliplatin or Capecitabine Plus Oxaliplatin for Patients with Gastric Cancer After D2 Gastrectomy.
    Nakamura Y; Yamanaka T; Chin K; Cho H; Katai H; Terashima M; Misawa K; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Bando H; Kawashima Y; Fukunaga T; Gotoh M; Ishibashi T; Shitara K
    Ann Surg Oncol; 2019 Feb; 26(2):465-472. PubMed ID: 30456678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study.
    Fuse N; Bando H; Chin K; Ito S; Yoshikawa T; Tsuburaya A; Terashima M; Kawashima Y; Fukunaga T; Gotoh M; Emi Y; Yoshida K; Oki E; Takahashi S; Kuriki H; Sato K; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):332-340. PubMed ID: 26956689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.
    Ito S; Sano T; Mizusawa J; Takahari D; Katayama H; Katai H; Kawashima Y; Kinoshita T; Terashima M; Nashimoto A; Nakamori M; Onaya H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):322-331. PubMed ID: 27299887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
    Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
    Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
    Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
    Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine.
    Lee KW; Kim BJ; Kim MJ; Han HS; Kim JW; Park YI; Park SR
    Cancer Res Treat; 2017 Jul; 49(3):706-716. PubMed ID: 27764906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I/II study of a combination of docetaxel, capecitabine, and cisplatin (DXP) as first-line chemotherapy in patients with advanced gastric cancer.
    Kang YK; Ryu MH; Yoo C; Chang HM; Yook JH; Oh ST; Kim BS; Kim TW
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1435-43. PubMed ID: 20811894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
    Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
    Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.
    Lee CK; Jung M; Kim HS; Jung I; Shin DB; Kang SY; Zang DY; Kim KH; Lee MH; Kim BS; Lee KH; Cheong JH; Hyung WJ; Noh SH; Chung HC; Rha SY
    Cancer Res Treat; 2019 Jan; 51(1):1-11. PubMed ID: 29397659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
    Peng L; Yang W; Zhang Z; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy.
    Fujitani K; Tamura S; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Shimokawa T; Tsujinaka T; Furukawa H
    Gastric Cancer; 2014 Apr; 17(2):348-53. PubMed ID: 23736741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.